248 related articles for article (PubMed ID: 23275335)
1. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.
So L; Yea SS; Oak JS; Lu M; Manmadhan A; Ke QH; Janes MR; Kessler LV; Kucharski JM; Li LS; Martin MB; Ren P; Jessen KA; Liu Y; Rommel C; Fruman DA
J Biol Chem; 2013 Feb; 288(8):5718-31. PubMed ID: 23275335
[TBL] [Abstract][Full Text] [Related]
2. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; Acosta YY; Herranz J; Martínez S; Blanco-Aparicio C; Criado G; Pastor J; Dianzani U; Portolés P; Rojo JM
Biochem Pharmacol; 2016 Apr; 106():56-69. PubMed ID: 26883061
[TBL] [Abstract][Full Text] [Related]
3. Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling.
Vantler M; Jesus J; Leppänen O; Scherner M; Berghausen EM; Mustafov L; Chen X; Kramer T; Zierden M; Gerhardt M; Ten Freyhaus H; Blaschke F; Sterner-Kock A; Baldus S; Zhao JJ; Rosenkranz S
Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1434-44. PubMed ID: 25908763
[TBL] [Abstract][Full Text] [Related]
4. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.
Jamieson S; Flanagan JU; Kolekar S; Buchanan C; Kendall JD; Lee WJ; Rewcastle GW; Denny WA; Singh R; Dickson J; Baguley BC; Shepherd PR
Biochem J; 2011 Aug; 438(1):53-62. PubMed ID: 21668414
[TBL] [Abstract][Full Text] [Related]
5. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
[TBL] [Abstract][Full Text] [Related]
6. The PI-3-Kinase P110α Catalytic Subunit of T Lymphocytes Modulates Collagen-Induced Arthritis.
Montes-Casado M; Ojeda G; Criado G; Rojo JM; Portolés P
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203838
[TBL] [Abstract][Full Text] [Related]
7. Activity of any class IA PI3K isoform can sustain cell proliferation and survival.
Foukas LC; Berenjeno IM; Gray A; Khwaja A; Vanhaesebroeck B
Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11381-6. PubMed ID: 20534549
[TBL] [Abstract][Full Text] [Related]
8. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.
Yea SS; So L; Mallya S; Lee J; Rajasekaran K; Malarkannan S; Fruman DA
PLoS One; 2014; 9(6):e99486. PubMed ID: 24915189
[TBL] [Abstract][Full Text] [Related]
9. Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.
Höland K; Boller D; Hagel C; Dolski S; Treszl A; Pardo OE; Cwiek P; Salm F; Leni Z; Shepherd PR; Styp-Rekowska B; Djonov V; von Bueren AO; Frei K; Arcaro A
PLoS One; 2014; 9(4):e94132. PubMed ID: 24718026
[TBL] [Abstract][Full Text] [Related]
10. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
11. Biased binding of class IA phosphatidyl inositol 3-kinase subunits to inducible costimulator (CD278).
Acosta YY; Zafra MP; Ojeda G; Bernardone IS; Dianzani U; Portolés P; Rojo JM
Cell Mol Life Sci; 2011 Sep; 68(18):3065-79. PubMed ID: 21188463
[TBL] [Abstract][Full Text] [Related]
12. T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response.
Aragoneses-Fenoll L; Ojeda G; Montes-Casado M; Acosta-Ampudia Y; Dianzani U; Portolés P; Rojo JM
Front Immunol; 2018; 9():332. PubMed ID: 29535720
[TBL] [Abstract][Full Text] [Related]
13. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
Papakonstanti EA; Zwaenepoel O; Bilancio A; Burns E; Nock GE; Houseman B; Shokat K; Ridley AJ; Vanhaesebroeck B
J Cell Sci; 2008 Dec; 121(Pt 24):4124-33. PubMed ID: 19033389
[TBL] [Abstract][Full Text] [Related]
14. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells.
Bilancio A; Okkenhaug K; Camps M; Emery JL; Ruckle T; Rommel C; Vanhaesebroeck B
Blood; 2006 Jan; 107(2):642-50. PubMed ID: 16179367
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of P110α and P110δ catalytic subunits of PI3 kinase reverses impaired arterial healing after injury in hypercholesterolemic male mice.
Chaudhuri P; Smith AH; Graham LM; Rosenbaum MA
Am J Physiol Cell Physiol; 2021 Jun; 320(6):C943-C955. PubMed ID: 33689479
[TBL] [Abstract][Full Text] [Related]
16. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling.
Chaussade C; Rewcastle GW; Kendall JD; Denny WA; Cho K; Grønning LM; Chong ML; Anagnostou SH; Jackson SP; Daniele N; Shepherd PR
Biochem J; 2007 Jun; 404(3):449-58. PubMed ID: 17362206
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic mutations of p110α isoform of PI 3-kinase upregulate its protein kinase activity.
Buchanan CM; Dickson JM; Lee WJ; Guthridge MA; Kendall JD; Shepherd PR
PLoS One; 2013; 8(8):e71337. PubMed ID: 23936502
[TBL] [Abstract][Full Text] [Related]
18. VEGF-mediated PI3K class IA and PKC signaling in cardiomyogenesis and vasculogenesis of mouse embryonic stem cells.
Bekhite MM; Finkensieper A; Binas S; Müller J; Wetzker R; Figulla HR; Sauer H; Wartenberg M
J Cell Sci; 2011 Jun; 124(Pt 11):1819-30. PubMed ID: 21540297
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis.
Soler A; Serra H; Pearce W; Angulo A; Guillermet-Guibert J; Friedman LS; Viñals F; Gerhardt H; Casanovas O; Graupera M; Vanhaesebroeck B
J Exp Med; 2013 Sep; 210(10):1937-45. PubMed ID: 24043760
[TBL] [Abstract][Full Text] [Related]
20. PI3K p110α/Akt signaling negatively regulates secretion of the intestinal peptide neurotensin through interference of granule transport.
Li J; Song J; Cassidy MG; Rychahou P; Starr ME; Liu J; Li X; Epperly G; Weiss HL; Townsend CM; Gao T; Evers BM
Mol Endocrinol; 2012 Aug; 26(8):1380-93. PubMed ID: 22700584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
